Maternal Immune Activation with the Viral Mimetic Poly:IC in Pregnant Rats

Materials and Reagents

1. 25 Gauge needles (BD PrecisionGlide^TM needle, catalog number: 14-826AA )

2. Antiseptic isopropyl alcohol pad, sterile, medium (Alliance^®, catalog number: 211-MM-05507 )

3. Syringes (3 ml) (BD, Luer-Lok^TM Tip, catalog number: B309657 )

4. Virgin female Sprague-Dawley rats

5. Male Sprague-Dawley rats

6. Poly:IC HMW (InvivoGen, Catalog code: tlrl-pic-5 )

7. Vaseline (Vaseline^® Petroleum Jelly Original)

8. Sterile normal saline (0.9%) (Hospira^®)

Equipment

1. Pipette 200 μl (Eppendorf Research^® plus, catalog number: 3124000083 )

2. Heating pads (Sunbeam^®, Standard size, catalog number: 730AO-CAD-MASTER )

3. Beaker flask (300 ml)

4. Scale suitable for weighing rats

5. Thermometer

6. Rodent rectal temperature probe (Physitemp, model: BAT-12 )

7. Hot plate (Thermolyne, Nuova II )

8. Isofluorane machine suitable for rats (ARVS)

9. Fume hood (Hamilton, SafeAire II, model: HMLAB027 )

10. Light microscope (Boreal 2 Digital Compound Microscopes–HM Series)

Procedure

1. Breeding

   1. Male and female rats (approximately 60 days old) are delivered to the vivarium, housed in same sex pairs, and given one week to acclimatize before experimentation. In our facility, male and female rats are housed in the same colony room in standard ventilated cages. Food and water are provided ad libitum throughout the experiment. The light-dark cycle is 12 h:12 h (lights on at 7 am) in our facility.

   2. Handle female rats for 3 min on 3 consecutive days before breeding.

   3. One day before breeding, separate male rats into individual cages.

   4. Approximately 1 h before the start of the dark cycle, place female rats with a male rat of the same strain (ratio 2 females in each male cage) and leave overnight.

   5. Approximately one hour after the light cycle begins (i.e., 14 h after pairing), remove the female rats from the male’s cage. Immediately collect a sample from the vagina of each rat with a sterile P200 pipette tip filled with 50-60 μl of sterile physiological saline. To achieve this, gently restrain each rat and pipette the saline into the vaginal canal, then retract the saline back into the pipette and eject onto a clean glass microscope slide. If the rat urinates, wait until urination stops before taking the sample.

   6. Always use a new pipette tip for each rat.

   7. Using a light microscope, check for the presence of spermatozoa (see Lucio et al., 2013 [Figure 2A] for an example photomicrograph of rat spermatozoa).

      Important: It is not necessary to stain the slides, but it is necessary to visualize the cells collected before the solution dries.

   8. If spermatozoa are present, the rat is considered pregnant. That day is then considered day 0 of gestation.

   9. Place the pregnant rat in a new home cage and begin monitoring body weight and food intake. Care should be taken to minimize disturbances during pregnancy. In our protocol, body weight is monitored weekly when the cages are changed. Specific experimental considerations may necessitate more frequent monitoring of the pregnant dams.

   10. Rats that are not suspected to be pregnant should be placed back in their home cage (i.e., separated from the male) until they are re-paired. There is some risk that rats believed not to be pregnant actually are. If possible, wait 1-2 weeks before re-pairing. Monitor body weight during this time as rats that are pregnant will show an increase in body weight during the first 14 days of pregnancy.

   11. On the day that re-pairing is desired, proceed with Step A2 again.

       
       

2. Poly:IC preparation

   1. Poly:IC is prepared according to the manufacture’s instructions (poly:IC, High Molecular Weight (HMW), InvivoGen, San Diego, CA). Note that some researchers also use polyI:C sodium salt from Sigma Aldrich.

   2. To improve the solubility of the polyI:C, we heat it up in a 300 ml beaker filled with distilled water (150 ml). Using a hot plate, heat the distilled water to a maximum of 65 °C and place the bottle containing the polyI:C solution in the distilled water for 10 min.

   3. Shake the bottle containing the polyI:C carefully and slowly when done.

   4. Allow the polyI:C to cool for 1 h at room temperature.

   5. Prepare appropriate aliquots for the number of rats to be treated and store at 4 °C or -20 °C. The poly:IC solution is stable for 1 month at 4 °C and 1 year at -20 °C.

      
      

3. Poly:IC treatment

   1. On gestational day (GD) 15, the pregnant rats are removed from their colony room one at a time, weighed, and rectal temperature is taken. Use vaseline to aid insertion of the rectal probe.

   2. Place the rat inside the anesthesia induction chamber. Induce anesthesia with 5% isofluorane.

   3. Once the rat is anesthetized, remove the rat from the induction chamber and place into a fume hood on a heating pad with a nose cone over its face to maintain anesthesia (2.5% isofluorane is typically sufficient for maintenance).

   4. Pinch the rat’s toes to ensure that it is sufficiently anesthetized. In the absence of a reaction, treatment can proceed.

   5. Before the injection, clean the tail with an antiseptic isopropyl alcohol pad and then locate one of the two lateral tail veins in the middle third of the tail. With the needle point orientated bevel up, insert just below the surface and into the vein. Inject the appropriate amount of poly:IC or sterile physiological saline (control group) with a 25 Gauge needle. When the needle is placed appropriately, the plunger will depress easily with no resistance. If resistance is felt, remove the needle and try again at a position higher on the tail or on the opposite tail vein. We typically administer 4 mg/kg of polyI:C (Lins et al., 2018 and 2019).

   6. Turn off the anesthesia and transfer the rat back into her home cage. The rat should be on a heating pad from the time she is placed under anesthesia to the time she completely wakes up. Once the rat is awake and can maintain balance, she can be returned to the colony room.

   7. Our protocol typically involves monitoring weight and temperature 3, 8, 24 and 48 h following treatment. These measurements are taken quickly in a procedure room just outside the rats’ colony room. Body temperature can be a key measure of sickness response in the MIA model. The effect of Poly:IC on body temperature is usually demonstrated as a biphasic response, with an early hyperthermia (3 h-6 h) followed by a delayed hypothermia. Regarding hypothermia, if a dam’s body temperature is below 36 °C, it is necessary to provide access to a warming pad in their home cage for 24 h until their temperature returns to normal. In the case of persistent hypothermia, euthanasia may be necessary.

   8. Pregnant rats deliver their litters naturally. Starting on gestational day 20, we check for litters twice per day during the light cycle. The day of birth is noted as postnatal day 0.

   9. On postnatal day 1, remove dams and litters one at a time from the colony to a nearby procedure room. Before handling the pups, place the dam in a holding cage. While handling the pups as little as possible, count and sex them, and weigh as a group. We typically cull litters back to 10 pups with a roughly balanced sex ratio where possible.

Notes

1. Variability in the published protocols for maternal immune activation exists (Kentner et al., 2019). In an effort to improve reproducibility, a checklist for reporting methodological details has been developed and should be used in all future studies using maternal immune activation (Kentner et al., 2019). Careful consideration must be given to sample sizes given that offspring from a given litter cannot be considered independent samples (see Kentner et al., 2019 and references therein).

2. Successful MIA can be observed with the increased maternal proinflammatory cytokines (such as CXCL1, IL-6, IL-1β TNF-α) after poly:IC treatment (reviewed in Bergdolt and Dunaevsky, 2019). Also, previous studies have observed some behavioral phenotypes such as prepulse inhibition deficits in MIA offspring (Dickerson et al., 2010; Yee et al., 2011; Giovanoli et al., 2016; Meehan et al., 2017), impairments in sociability and cognitive domains (Vorhees et al., 2015; Mattei et al., 2017; Lins et al., 2018). Furthermore, some studies also reported hypolocomotive behavior in poly:IC treated offspring (Van den Eynde et al., 2014). Another relevant behavioral phenotype observed in MIA offspring is increased locomotor activity induced by amphetamine, an indirect dopamine receptor agonist, or dizocilpine (MK-801), an NMDA receptor antagonist (Meyer et al., 2008; Vorhees et al., 2015; Lins et al., 2018).

3. Variability in methods for MIA induction include differences in animal strain, doses of polyI:C, time of treatment (early, mid, or late gestation), route of administration (intraperitoneal, sub-cutaneous, intra-venous), and source of polyI:C (Meyer et al., 2006 and 2008; Careaga et al., 2018; Mueller et al., 2019; Kowash et al., 2019; Kentner et al., 2019). As a result of these different induction protocols, some variablitlies in behavioral response can be observed. For example, previous studies showed impaired pre-pulse inhibition (PPI) in polyI:C offspring (reviewed in Meyer and Feldon, 2009, Mattei et al., 2014) while others did not (Lins et al., 2018, 2019; Van den Eynde et al., 2014). Our previous data also demonstrated that polyI:C offspring showed heightened sensitivity to MK-801 (Lins et al., 2018); this finding replicates previous studies which report hyperlocomotion following MK-801 (Zuckerman and Weiner, 2005).

Acknowledgments

This protocol is adapted from the protocol used by Lins et al. (2018 and 2019). TMS received fellowship from the Saskatchewan Health Research Foundation. BRL received support from the University of Saskatchewan.

Competing interests

Research in the Howland laboratory is funded by peer reviewed research grants from government agencies and charities. The authors have no financial or other competing interests to declare.

Ethics

Experimental protocols and the use of animals were approved by the University of Saskatchewan Animal Research Ethics Board and conformed to the guidelines of the Canadian Council on Animal Care. Research conducted was approved under protocol 20080107 which has been active from 2008 to the present time.

References

1. Bergdolt, L. and Dunaevsky, A. (2019). Brain changes in a maternal immune activation model of neurodevelopmental brain disorders. Prog Neurobiol 175: 1-19.
2. Brown, A. S. and Meyer, U. (2018). Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry 175: 1073-1083.
3. Careaga, M., Murai, T. and Bauman, M. D. (2017). Maternal immune activation and autism spectrum disorder: from rodents to nonhuman and human primates. Biol Psychiatry 81: 391-401.
4. Careaga, M., Taylor, S. L., Chang, C., Chiang, A., Ku, K. M., Berman, R. F., Van de Water, J. A. and Bauman, M. D. (2018). Variability in poly:IC induced immune response: Implications for preclinical maternal immune activation models. J Neuroimmunol 323: 87-93.
5. Dickerson, D. D., Wolff, A. R. and Bilkey, D. K. (2010). Abnormal long-range neural synchrony in a maternal immune activation animal model of schizophrenia. J Neurosci 30: 12424-12431.
6. Estes, M. L. and McAllister, A. K. (2016). Maternal immune activation: implications for neuropsychiatric disorders. Science 353: 772-777.
7. Giovanoli, S., Weber-Stadlbauer, U., Schedlowski, M., Meyer, U. and Engler, H. (2016). Prenatal immune activation causes hippocampal synaptic deficits in the absence of overt microglia anomalies. Brain, Beh Immun 55: 25-38.
8. Gumusoglu, S. B. and Stevens, H. E. (2019). Maternal inflammation and neurodevelopmental programming: a review of preclinical outcomes and implications for translational psychiatry. Biol Psychiatry 85: 107-121.
9. Kentner, A. C., Bilbo, S. D., Brown, A. S., Hsiao, E. Y., McAllister, A. K., Meyer, U., Pearce, B. D., Pletnikov, M. V., Yolken, R. H. and Bauman, M. D. (2019). Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model. Neuropsychopharmacology 44: 245-258.
10. Kowash, H. M., Potter, H. G., Edye, M. E., Prinssen, E. P., Bandinelli, S., Neill, J. C., Hager, R. and Glazier, J. D. (2019). Poly(I:C) source, molecular weight and endotoxin contamination affect dam and prenatal outcomes, implications for models of maternal immune activation. Brain Behav Immun 82: 160-166.
11. Lins, B. R., Hurtubise, J. L., Roebuck, A. J., Marks, W. N., Zabder, N. K., Scott, G. A., Greba, Q., Dawicki, W., Zhang, X., Rudulier, C. D., Gordon, J. R. and Howland, J. G. (2018). Prospective analysis of the effects of maternal immune activation on rat cytokines during pregnancy and behavior of the male offspring relevant to schizophrenia. eNeuro 5(4). pii: ENEURO.0249-18.
12. Lins, B. R., Marks, W. N., Zabder, N. K., Greba, Q. and Howland, J. G. (2019). Maternal immune activation during pregnancy alters the behavior profile of female offspring of Sprague Dawley rats. eNeuro 6(2). pii: ENEURO.0437-18.
13. Lucio, R. A., Tlachi-López, J. L., Eguibar, J. R. and Agmo, A. (2013). Sperm count and sperm motility decrease in old rats. Physiol Behav 111: 73-79.
14. Mattei, D., Djodari-Irani, A., Hadar, R., Pelz, A., de Cossio, L. F., Goetz, T., Matyash, M., Kettenmann, H., Winter, C. and Wolf, S. A. (2014). Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain Behav Immun 38: 175-184.
15. Mattei, D., Ivanov, A., Ferrai, C., Jordan, P., Guneykaya, D., Buonfiglioli, A., Schaafsma, W., Przanowski, P., Deuther-Conrad, W., Brust, P., Hesse, S., Patt, M., Sabri, O., Ross, T. L., Eggen, B. J. L., Boddeke, E., Kaminska, B., Beule, D., Pombo, A., Kettenmann, H. and Wolf, S. A. (2017). Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment. Transl Psychiatry 7(5): e1120.
16. Meehan, C., Harms, L., Frost, J. D., Barreto, R., Todd, J., Schall, U., Shannon Weickert, C., Zavitsanou, K., Michie, P. T. and Hodgson, D. M. (2017). Effects of immune activation during early or late gestation on schizophrenia-related behaviour in adult rat offspring. Brain Behav Immun 63: 8-20.
17. Meyer, U., Nyffeler, M., Engler, A., Urwyler, A., Schedlowski, M., Knuesel, I., Yee, B. K. and Feldon, J. (2006). The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 26(18): 4752-4762.
18. Meyer, U., Nyffeler, M., Yee, B. K., Knuesel, I. and Feldon, J. (2008). Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 22(4): 469-486.
19. Meyer, U. and Feldon, J. (2009). Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 204(2): 322-334.
20. Meyer, U., (2019). Neurodevelopmental resilience and susceptibility to maternal immune activation. Trends Neurosci 42: 793-806.
21. Mueller, F. S., Richetto, J., Hayes, L. N., Zambon, A., Pollak, D. D., Sawa, A., Meyer, U. and Weber-Stadlbauer, U. (2019). Influence of poly(I:C) variability on thermoregulation, immune responses and pregnancy outcomes in mouse models of maternal immune activation. Brain Behav Immun 80: 406-418.
22. Piontkewitz, Y., Arad, M. and Weiner, I. (2012). Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology 62: 1273-1289.
23. Reisinger, S., Khan, D., Kong, E., Berger, A., Pollak, A. and Pollak, D. D. (2015). The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther 149: 213-226.
24. Shi, L., Fatemi, S. H., Sidwell, R. W. and Patterson, P. H. (2003). Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23: 297-302.
25. K., Van den Eynde, Missault, S., Fransen, E., Raeymaekers, L., Willems, R., Drinkenburg, W., Timmermans, J. P., Kumar-Singh, S. and Dedeurwaerdere, S. (2014). Hypolocomotive behaviour associated with increased microglia in a prenatal immune activation model with relevance to schizophrenia. Behav Brain Res 258: 179-186.
26. Vorhees, C. V., Graham, D. L., Braun, A. A., Schaefer, T. L., Skelton, M. R., Richtand, N. M. and Williams, M. T. (2015). Prenatal immune challenge in rats: effects of polyinosinic-polycytidylic acid on spatial learning, prepulse inhibition, conditioned fear, and responses to MK-801 and amphetamine. Neurotoxicol Teratol 47: 54-65.
27. Yee, N., Ribic, A., de Roo, C. C. and Fuchs, E. (2011). Differential effects of maternal immune activation and juvenile stress on anxiety-like behaviour and physiology in adult rats: no evidence for the"double-hit hypothesis. Behav Brain Res 224(1): 180-188.
28. Zuckerman, L. and Weiner, I. (2005). Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39(3): 311-323.